Manuscripts
Showing 1530 manuscripts.
Weight changes and adverse pregnancy outcomes with dolutegravir-and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum
Citation
Risa M. Hoffman, Sean Brummel, Lauren Ziemba, Lameck Chinula, Jeffrey S A Stringer, Frances Nakayiwa, Avy Violari, Lee Fairlie, Victoria Ndyanabangi, Teacler G. Nematadzira, Sherika Hanley, Esau João, Linda Aurpibul, Mario Dias Correa Junior, Oranich Navanukroh, Neetal Nevrekar, Gerhard Theron, Cristina Barroso Hofer, Rebecca Zash, Roger Shapiro, Nahida Chakhtoura, Ben Johnston, Chelsea Krotje, Katie McCarthy, Patrick Jean-Philippe, Paul Sax, Judith S. Currier, Shahin Lockman, VESTED Study Team. Weight changes and adverse pregnancy outcomes with dolutegravir-and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum. Clinical Infectious Diseases. 2024. ciae001PMID: 38180851Year
2024
Journal
Clinical Infectious Diseases
Study
IMPAACT 2010
Self-reported Antiretroviral Adherence: Association With Maternal Viral Load Suppression in Postpartum Women Living With HIV-1 From Promoting Maternal and Infant Survival Everywhere, a Randomized Controlled Trial in Sub-Saharan Africa and India
Citation
Neetal Nevrekar, Kevin Butler, David E. Shapiro, Patience Atuhaire, Taha E Taha, Bonus Makanani, Lameck Chinula, Maxensia Owor, Dhayendre Moodley, Tsungai Chipato, Katie McCarthy, Patricia M. Flynn, Judith Currier, Mary Glenn Fowler, Amita Gupta, Nishi Suryavanshi. Self-reported Antiretroviral Adherence: Association With Maternal Viral Load Suppression in Postpartum Women Living With HIV-1 From Promoting Maternal and Infant Survival Everywhere, a Randomized Controlled Trial in Sub-Saharan Africa and India. Journal of the International AIDS Society. 2023. 92: 76-83. PMID: 36170749Year
2023
Journal
Journal of the International AIDS Society
Study
1077BF, 1077FF
Dolutegravir Plasma Protein Binding and Unbound Concentrations During Pregnancy and Postpartum
Citation
Jeremiah D. Momper, Mina Nikanjam, Brookie M. Best, Mark Mirochnick, Edmund V. Capparelli, Tim R. Cressey. Dolutegravir Plasma Protein Binding and Unbound Concentrations During Pregnancy and Postpartum. Journal of Acquired Immune Deficiency Syndromes. 2023. 94: 332-336. PMID: 37884053Year
2023
Journal
Journal of Acquired Immune Deficiency Syndromes
Study
P1026S
Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s
Citation
Marije Van Schalkwyk, Adrie Bekker, Eric Decloedt, Jiajia Wang, Gerhard B. Theron, Mark F. Cotton, Ahizechukwu C. Eke, Tim R. Cressey, David E. Shapiro, Kira Bacon, Kevin Knowles, Kathleen George, Renee Browning, Nahida Chakhtoura, Kittipong Rungruengthanakit, Lubbe Wiesner, Edmund V. Capparelli, Alice M. Stek, Mark Mirochnick, Brookie M. Best, IMPAACT P1026s Protocol Team. Pharmacokinetics and safety of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum: results from IMPAACT P1026s. Journal Antimicrobial Agents and Chemotherapy. 2023. 67: e0073723. PMID: 37882552Year
2023
Journal
Journal Antimicrobial Agents and Chemotherapy
Study
P1026S
Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial
Citation
Amita Gupta, Priya Singh, Lisa Aaron, Grace Montepiedra, Tsungai Chipato, Lynda Stranix-Chibanda, Vongai Chanaiwa, Tichaona Vhembo, Mercy Mutambanengwe, Gaerolwe Masheto, Mpho Raesi, Sarah Bradford, Amanda Golner, Diane Costello, Vandana Kulkarni, Aisa Shayo, Enid Kabugho, Patrick Jean–Phillippe, Nahida Chakhtoura, Timothy R. Sterling, Gerhard Theron, Adriana Weinberg, IMPAACT P1078 TB APPRISE Study Team. Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. Lancet Child and Adolescent Health. 2023. 7: 708-717. PMID: 37634517Year
2023
Journal
Lancet Child and Adolescent Health
Study
P1078
Pharmacokinetics, Safety, and Tolerability of Dispersible and Immediate-Release Abacavir, Dolutegravir and Lamivudine Tablets in Children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study
Citation
Kristina M. Brooks, Jennifer J. Kiser, Lauren Ziemba, Shawn Ward, Yasha Rani, Tim R. Cressey, Gaerolwe R. Masheto, Haseena Cassim, Jaime G. Deville, Ponego L. Ponatshego, Faeezah Patel, Linda Aurpibul, Shaun L. Barnabas, Iris Mustich, Anne Coletti, Barbara Heckman, Chelsea Krotje, Mark Lojacono, Dwight E. Yin, Ellen Townley, Jack Moye, Sai Majji, Edward P. Acosta, Kevin Ryan, Hardik Chandasana, Cynthia H. Brothers, Ann M. Buchanan, Helena Rabie, Patricia M. Flynn, IMPAACT 2019 Study Team. Pharmacokinetics, Safety, and Tolerability of Dispersible and Immediate-Release Abacavir, Dolutegravir and Lamivudine Tablets in Children with HIV (IMPAACT 2019): week 24 results of an open-label, multicentre, phase 1-2 dose-confirmation study. Lancet HIV. 2023. 10: E506-E517. PMID: 37541705Year
2023
Journal
Lancet HIV
Study
IMPAACT 2019
A Per-Protocol Analysis using Inverse Probability of Censoring Weights in a Randomized Trial of Initial PI versus NNRTI Regimens in Children
Citation
Dwight E. Yin, Stephen R. Cole, Christina Ludema, M. Alan Brookhart, Carol E. Golin, William C. Miller, Ross E. McKinney. A Per-Protocol Analysis using Inverse Probability of Censoring Weights in a Randomized Trial of Initial PI versus NNRTI Regimens in Children. American Journal Of Epidemiology. 2023. 192: 916-928. PMID: 36896583Year
2023
Journal
American Journal Of Epidemiology
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial
Citation
Lameck Chinula, Lauren Ziemba, Sean Brummel, Katie McCarthy, Anne Coletti, Chelsea Krotje, Benjamin Johnston, Kevin Knowles, Sikhulile Moyo, Lynda Stranix-Chibanda, Risa Hoffman, Paul E Sax, Jeffrey Stringer, Nahida Chakhtoura, Patrick Jean-Philippe, Violet Korutaro, Haseena Cassim, Lee Fairlie, Gaerolwe Masheto, Ceejay Boyce, Lisa M Frenkel, K Rivet Amico, Lynette Purdue, Roger Shapiro, Blandina Theophil Mmbaga, Faeezah Patel, Jean van Wyk, James F Rooney, Judith S Currier, Shahin Lockman, IMPAACT 2010/VESTED Study Team and Investigators. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet HIV. 2023. S2352-3018: 00061-9. PMID: 37167996Year
2023
Journal
Lancet HIV
Study
IMPAACT 2010
Markers of intestinal immune activation and inflammation are not associated with preterm birth among women with low level HIV viremia
Citation
Anna Maya Powell, Deborah Persaud, Jean Rene Anderson, Deborah Kacanek, Yanling Huo, Kevin Psoter, Lisa R Yanek, Khalil Ghanem, Irina Burd, International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) 1025 protocol team. Markers of intestinal immune activation and inflammation are not associated with preterm birth among women with low level HIV viremia. American Journal of Reproductive Immunology. 2023. PMID: 36680487Year
2023
Journal
American Journal of Reproductive Immunology
Study
P1025
Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial
Citation
Ashenafi S Cherkos, Sylvia M LaCourse, Daniel A Enquobahrie, Barbra A Richardson, Sarah Bradford, Grace Montepiedra, Blandina T Mmbaga, Tapiwa Mbengeranwa, Gaerolwe Masheto, Patrick Jean-Phillippe, Nahida Chakhtoura, Gerhard Theron, Adriana Weinberg, Haseena Cassim, Mpho S Raesi, Elsie Jean, Deo Wabwire, Teacler Nematadzira, Lynda Stranix-Chibanda, Anneke C Hesseling, Linda Aurpibul, Amita Gupta, Grace John-Stewart, IMPAACT P1078 TB APPRISE Study Team. Effect of pregnancy versus postpartum maternal isoniazid preventive therapy on infant growth in HIV-exposed uninfected infants: a post-hoc analysis of the TB APPRISE trial. eClinicalMedicine. 2023. 58: 101912. PMID: 36969345Year
2023
Journal
eClinicalMedicine
Study
P1078